Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

October 06, 2005 12:33 ET

Bioxel Pharma Announces the Eligibility of its Common Shares to the SME Growth Stock Plan

SAINTE-FOY, QUEBEC--(CCNMatthews - Oct. 6, 2005) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane API's and developer of targeted oncology drugs, announces it has obtained an advance ruling from the ministère du Revenu du Québec confirming that its common shares are eligible as valid shares pursuant to the SME Growth Stock Plan.

As a result, common shares of Bioxel purchased on the secondary market can be used to replace a qualifying share or security disposed of by an individual for a covering operation in accordance with the SME Growth Stock Plan.

Common shares of Bioxel have been included on the list of valid shares drawn up by the Autorité des marchés financiers ("AMF").

ABOUT BIOXEL PHARMA

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane API's and taxane-based proprietary products for improved cancer therapy.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Officer
    (418) 654-9666
    www.bioxelpharma.com